Login to Your Account



Cephalon Buying Out Salmedix: $160M Cash, $40M Milestones

By Randall Osborne


Monday, May 16, 2005
Cephalon Inc. topped off a spate of mixed news with disclosure of its plan to buy Salmedix Inc. for about $160 million in cash, adding to the cancer drug pipeline while taking on $40 million in potential milestone payments related to Treanda, Salmedix's Phase II candidate for slowly progressing non-Hodgkin's lymphoma. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription